Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Ross

Showing results (111-120 of 130) with videos related to

Pageof 13
Sort By:
Blood Advances|May 7, 2025
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosisDavid M Ross, Florian H Heidel, Andrew C Perkins, et al.
Ejhaem|August 21, 2023
Incidence of blast phase in myelofibrosis according to anemia severityBarbara Mora, Margherita Maffioli, Elisa Rumi, et al.
Blood|December 19, 2014
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsDavid T Yeung, Michael P Osborn, Deborah L White, et al.
Blood Advances|April 29, 2026
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 studyHarinder Gill, Abdulraheem Yacoub, Aaron T Gerds, et al.
Internal Medicine Journal|December 26, 2023
Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignanciesAshlea Campbell, Benjamin Teh, Stephen Mulligan, et al.
Haematologica|March 23, 2023
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment interventionNaranie Shanmuganathan, Carol Wadham, NurHezrin Shahrin, et al.
Nature|March 23, 2017
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1Andrew A Wylie, Joseph Schoepfer, Wolfgang Jahnke, et al.
Blood|September 14, 2021
Childhood acute myeloid leukemia shows a high level of germline predispositionSaumya E Samaraweera, Paul P S Wang, Ka Leung Li, et al.
Nature Communications|July 15, 2022
Author Correction: Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemiaMahmoud A Bassal, Saumya E Samaraweera, Kelly Lim, et al.
Nature Communications|May 13, 2022
Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemiaMahmoud A Bassal, Saumya E Samaraweera, Kelly Lim, et al.
Pageof 13

Showing results (111-120 of 130) with videos related to

Sort By:
Pageof 13
Blood Advances|May 7, 2025
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosisDavid M Ross, Florian H Heidel, Andrew C Perkins, et al.
Ejhaem|August 21, 2023
Incidence of blast phase in myelofibrosis according to anemia severityBarbara Mora, Margherita Maffioli, Elisa Rumi, et al.
Blood|December 19, 2014
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsDavid T Yeung, Michael P Osborn, Deborah L White, et al.
Blood Advances|April 29, 2026
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 studyHarinder Gill, Abdulraheem Yacoub, Aaron T Gerds, et al.
Internal Medicine Journal|December 26, 2023
Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignanciesAshlea Campbell, Benjamin Teh, Stephen Mulligan, et al.
Haematologica|March 23, 2023
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment interventionNaranie Shanmuganathan, Carol Wadham, NurHezrin Shahrin, et al.
Nature|March 23, 2017
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1Andrew A Wylie, Joseph Schoepfer, Wolfgang Jahnke, et al.
Blood|September 14, 2021
Childhood acute myeloid leukemia shows a high level of germline predispositionSaumya E Samaraweera, Paul P S Wang, Ka Leung Li, et al.
Nature Communications|July 15, 2022
Author Correction: Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemiaMahmoud A Bassal, Saumya E Samaraweera, Kelly Lim, et al.
Nature Communications|May 13, 2022
Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemiaMahmoud A Bassal, Saumya E Samaraweera, Kelly Lim, et al.
Pageof 13